Evidence map›Paper›PMID 32440730›Full record

Trial reportEuropean journal of nutrition2020

Prebiotic effect of inulin-type fructans on faecal microbiota and short-chain fatty acids in type 2 diabetes: a randomised controlled trial.

Eline Birkeland, Sedegheh Gharagozlian, Kåre I Birkeland, Jørgen Valeur, Ingrid Måge, Ida Rud, Anne-Marie Aas

Erratum issued Registry-linked trialOpen access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in European journal of nutrition, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT02569684 (Effects of Prebiotics on GLP-1 in Type 2 Diabetes), which is not on this map. Cited by 117 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
117citing papers in PubMed, 8 pooled it
8.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02569684 nacompletednot on this map

Effects of Prebiotics on GLP-1 in Type 2 Diabetes

TypeinterventionalSponsorOslo University HospitalRan2015 to 2019Enrolled37ConditionsDiabetes Type 2ArmsPrebiotic fibers: oligofructose and inulin, Maltodextrin
3 · Its place in the literature

Who cites it

117 citing papers in PubMed, 8 syntheses or guidelines pooled it, 207 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

57 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Eline BirkelandSection of Nutrition and Dietetics, Division of Medicine, Department of Clinical Service, Oslo University Hospital, Oslo, Norway. eline.birkeland@ous-hf.no.ORCID http://orcid.org/0000-0001-7371-9495
Sedegheh GharagozlianSection of Nutrition and Dietetics, Division of Medicine, Department of Clinical Service, Oslo University Hospital, Oslo, Norway.
Kåre I BirkelandInstitute of Clinical Medicine, University of Oslo, Oslo, Norway.
Jørgen ValeurDepartment of Gastroenterology, Oslo University Hospital, Oslo, Norway.
Ingrid MågeNofima-Norwegian Institute of Food, Fisheries and Aquaculture Research, Ås, Norway.
Ida Rud *Nofima-Norwegian Institute of Food, Fisheries and Aquaculture Research, Ås, Norway.
Anne-Marie Aas *Section of Nutrition and Dietetics, Division of Medicine, Department of Clinical Service, Oslo University Hospital, Oslo, Norway.
Oslo University Hospital · NONofima · NO

Funding

Neuronal ensembles of drug context-induced impulsive decision makingR21DA036660 · NIDA · WASHINGTON STATE UNIVERSITY · PI FUCHS LOKENSGARD, RITA A, XIE, XIAOHU · 2014 to 2015
$425k
NIDA NIH HHS R21 DA036660
6 · The paper itself

Abstract

purposeCompared to a healthy population, the gut microbiota in type 2 diabetes presents with several unfavourable features that may impair glucose regulation. The aim of this study was to evaluate the prebiotic effect of inulin-type fructans on the faecal microbiota and short-chain fatty acids (SCFA) in patients with type 2 diabetes.

methodsThe study was a placebo controlled crossover study, where 25 patients (15 men) aged 41-71 years consumed 16 g of inulin-type fructans (a mixture of oligofructose and inulin) and 16-g placebo (maltodextrin) for 6 weeks in randomised order. A 4-week washout separated the 6 weeks treatments. The faecal microbiota was analysed by high-throughput 16S rRNA amplicon sequencing and SCFA in faeces were analysed using vacuum distillation followed by gas chromatography.

resultsTreatment with inulin-type fructans induced moderate changes in the faecal microbiota composition (1.5%, p = 0.045). A bifidogenic effect was most prominent, with highest positive effect on operational taxonomic units (OTUs) of Bifidobacterium adolescentis, followed by OTUs of Bacteroides. Significantly higher faecal concentrations of total SCFA, acetic acid and propionic acid were detected after prebiotic consumption compared to placebo. The prebiotic fibre had no effects on the concentration of butyric acid or on the overall microbial diversity.

conclusionSix weeks supplementation with inulin-type fructans had a significant bifidogenic effect and induced increased concentrations of faecal SCFA, without changing faecal microbial diversity. Our findings suggest a moderate potential of inulin-type fructans to improve gut microbiota composition and to increase microbial fermentation in type 2 diabetes.

trial registrationThe trial is registered at clinicaltrials.gov (NCT02569684).

Indexed as

Diabetes Mellitus, Type 2PrebioticsAdultAgedCross-Over StudiesFatty Acids, VolatileFecesFemaleFermentationGastrointestinal MicrobiomeHumansInulinMaleMiddle AgedRNA, Ribosomal, 16SFatty Acids, VolatileInulinPrebioticsRNA, Ribosomal, 16S16S rRNA sequencingFaecal bacteriaPrebioticsSCFAType 2 diabetes

Identifiers

PMID32440730
PMCPMC7501097
OpenAlexW3028293438

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.